CanAssist Breast provides additional information about the tumor by looking at expression levels of proteins present in it. Along with the existing pathology report, this test result helps identify the likelihood of cancer returning after surgery and whether the patient is likely to benefit from chemotherapy or not.
This test is not applicable for patients who are diagnosed with DCIS (Ductal Carcinoma In-Situ) Once patients meet the test eligibility criteria, doctors must prescribe CanAssist Breast to help personalize treatment decisions.
Patients with early-stage, invasive breast cancer
Lymph node-negative or up to 3 lymph node-positive
Patients with hormone receptor-positive (“ER+ and/or PR+”) and HER2- negative disease
Patients should not have gone through neoadjuvant chemotherapy
